Home / Market News / $OMER
benzinga Corporate Catalyst Impact 75/100 ● neutral

Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Oct 16, 2026, 10:22 AM UTC · Primary ticker $OMER

Omeros announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for its marketing authorization application for narsoplimab (YARTEMLEA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in Europe. This decision, following a re-examination, means Omeros will not be able to commercialize YARTEMLEA in the EU, limiting a significant potential revenue stream and geographic expansion for the drug.

Omeros received a negative opinion from the EMA's CHMP for its drug narsoplimab (YARTEMLEA) for TA-TMA in Europe, following a re-examination. This is a significant setback as it blocks Omeros from commercializing YARTEMLEA in the European Union, a major pharmaceutical market. While YARTEMLEA is approved in the U.S. and Omeros plans to continue expanding its use there and pursue other indications, the inability to access the EU market represents a lost revenue opportunity and limits the drug's global reach. This news is negative for Omeros in the short term due to the reduced market potential, but the company's focus on the U.S. market and other indications provides some long-term mitigation. Traders should consider the impact on Omeros's future revenue projections and its ability to secure licensing deals in Europe.

$OMER negative Rejection of key drug in major market
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.